By Chris Wack
Pliant Therapeutics shares were up 23% to $3.34 after the company said an independent Data Safety Monitoring Board is allowing it to begin the assembly of an outside expert panel to review unblinded data from an ongoing Phase 2b trial of bexotegrast in patients with idiopathic pulmonary fibrosis.
The biopharmaceutical company said the panel, consisting of experts in pulmonary diseases and biostatistics, will provide an independent recommendation to Pliant regarding the trial.
The panel will serve as part of an expanded DSMB with the goal to reach a consensus recommendation regarding the trial. The decision to assemble the outside panel was taken as the company hasn't been able, through review of blinded data, to determine the rationale for the DSMB's recommendation to pause enrollment and dosing in the trial.
Pliant expects this process to conclude in two to four weeks.
Following the DSMB's previously announced recommendation, Pliant voluntarily paused enrollment and dosing in the clinical trial. Pliant said it will continue to remain blinded in order to ensure data integrity of the clinical trial with the goal of maintaining its potential to serve as a registrational trial.
Write to Chris Wack at chris.wack@wsj.com
(END) Dow Jones Newswires
February 13, 2025 10:27 ET (15:27 GMT)
Copyright (c) 2025 Dow Jones & Company, Inc.
免責聲明：投資有風險，本文並非投資建議，以上內容不應被視為任何金融產品的購買或出售要約、建議或邀請，作者或其他用戶的任何相關討論、評論或帖子也不應被視為此類內容。本文僅供一般參考，不考慮您的個人投資目標、財務狀況或需求。TTM對信息的準確性和完整性不承擔任何責任或保證，投資者應自行研究並在投資前尋求專業建議。